iTeos Therapeutics, Inc. (ITOS)

iTeos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-134.41	-112.64	96.65	214.52	-38.03
Depreciation & Amortization	1.24	0.9	0.8	0.6	0.54
Stock-Based Compensation	29.94	27.02	21.56	13.79	4.29
Other Operating Activities	-13.59	-10.23	-1.72	0.01	-1.3
Change in Accounts Payable	-2.45	3.04	2.76	2.28	1.68
Change in Unearned Revenue	-0.57	-11.77	-267.23	277.65	1.79
Change in Income Taxes	4.44	-4.93	6.11	-7.54	-
Change in Other Net Operating Assets	17.22	4.87	29.87	11.83	5.87
Operating Cash Flow	-98.18	-103.76	-111.19	513.14	-25.18
Capital Expenditures	-1.63	-2.97	-0.94	-1.18	-0.36
Investment in Securities	-129.49	75.72	-445	-	-
Other Investing Activities	-0.03	-0.1	-0.12	-0.06	-0.02
Investing Cash Flow	-131.15	72.66	-446.06	-1.24	-0.38
Issuance of Common Stock	122.72	1.11	0.93	2.94	214.32
Other Financing Activities	-0.48	-	1.06	0.72	0.67
Financing Cash Flow	122.24	1.11	1.98	3.66	340.34
Foreign Exchange Rate Adjustments	-1.93	-3.6	-8.53	-3.18	1.68
Net Cash Flow	-109.02	-33.59	-563.8	512.38	316.46
Free Cash Flow	-99.81	-106.72	-112.13	511.96	-25.53
Free Cash Flow Margin	-285.18%	-847.34%	-41.90%	148.49%	-
Free Cash Flow Per Share	-2.47	-2.98	-2.97	13.55	-1.69
Cash Income Tax Paid	4.03	6.82	22.82	32.02	0.11
Levered Free Cash Flow	-64.35	-73.28	-150.04	431.68	-18.83
Unlevered Free Cash Flow	-64.35	-73.28	-150.04	431.68	-18.83
Change in Net Working Capital	-4.11	6	251.15	-265.4	-4.79

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q